Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

非小细胞肺癌EGFR-TKI治疗失败后小细胞肺癌转化

Liu Xiao-qing,Guo Wan-feng

Clinical Medication Journal（2013）

Cited 0|Views18
No score
Abstract
表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)治疗晚期非小细胞肺癌(NSCLC)的耐药分子机制逐渐明了,其中小细胞肺癌(SCLC)转化引发了学者极大关注。这种表型转化和伴发EGFR突变是肿瘤细胞异质性,或是肿瘤干细胞,或是某些分子事件使然,但无论那种机制均是推测且无直接证据。目前临床实践中对这种EGFR-TKI耐药转化为SCLC患者的治疗仅是经验分享,亦无更高级别的证据推荐。
More
Translated text
Key words
EGFR-TKI,Small-cell lung cancer,Drug resistance,Non-small-cell lung cancer
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined